Healthcare solutions company Evolent Health (NYSE:EVH) fell short of the market’s revenue expectations in Q4 CY2024, but ...

Welcome to the Evolent earnings conference call for the fourth quarter and year ended December 31, 2024. All participants ...

Citizens JMP raised the firm’s price target on Evolent Health (EVH) to $13 from $12 and keeps an Outperform rating on the shares. Evolent’s Q4 ...

JMP Securities analyst Constantine Davides reiterated a Buy rating on Option Care Health (OPCH – Research Report) today and set a price target ...

Evolent Health, Inc. ( NYSE: EVH) Q4 2024 Earnings Conference Call February 20, 2025 5:00 PM ET Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - ...

Discover key insights from Evolent Health's Q4 2024 earnings call, focusing on 30% revenue growth, contract renegotiations, projections for 2025, ...

NYSE EVH opened at $10.44 on Friday. Evolent Health has a one year low of $9.45 and a one year high of $35.00. The stock has a 50-day moving average of $10.75 and a 200 day moving average of $18. ...

Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth ...

Evolent Health Inc (EVH) reports robust revenue growth and strategic contract extensions, while navigating increased oncology ...

The healthcare technology company posted adjusted earnings per share of -$0.02 for Q4, missing the consensus estimate of $0.07. Revenue came in at $646.5 million, below analyst projections of $652.2 ...

Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, represe ...